Compare EU & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.5M | 472.9M |
| IPO Year | 2011 | 2015 |
| Metric | EU | ZVRA |
|---|---|---|
| Price | $2.10 | $10.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 2.2M | 694.8K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | $43,155,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $212.11 | $37.27 |
| Revenue Next Year | $29.88 | $53.42 |
| P/E Ratio | ★ N/A | $7.26 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $1.27 | $6.85 |
| 52 Week High | $4.19 | $13.16 |
| Indicator | EU | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 63.24 |
| Support Level | $1.66 | $8.29 |
| Resistance Level | $2.17 | $11.19 |
| Average True Range (ATR) | 0.13 | 0.40 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 78.72 | 98.12 |
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.